Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136474 · ClinicalTrials.gov registry record · Phase 2
Amifostine for Head and Neck Irradiation in Lymphoma
A Phase 2 study of Lymphoma and Non-Hodgkin's Lymphoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT00136474: Completed Phase 2 study of Lymphoma and Non-Hodgkin's Lymphoma, sponsored by Dana-Farber Cancer Institute.
NCT00136474 is a Phase 2 study of Lymphoma and Non-Hodgkin's Lymphoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 75 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00136474, a Phase 2 study of Lymphoma and Non-Hodgkin's Lymphoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is determine the effects (good and bad) amifostine has on radiation-induced side effects of lymphoma treatment.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Amifostine
Study Locations (2)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2003-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
What the finished NCT00136474 record still lists
NCT00136474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT00136474 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00136474 about?
NCT00136474 is a clinical study titled "Amifostine for Head and Neck Irradiation in Lymphoma". The purpose of this study is determine the effects (good and bad) amifostine has on radiation-induced side effects of lymphoma treatment.
What is the current status of trial NCT00136474?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2003-05. Estimated completion is 2009-03.
What conditions does trial NCT00136474 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin's Disease.
What interventions are being tested in trial NCT00136474?
The interventions under investigation include: Radiation Therapy (RADIATION), Amifostine (DRUG).
Who is sponsoring clinical trial NCT00136474?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00136474 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00136474's enrollment target sits among peer trials
75 110th of 299 higher than 188 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia